Business Context and Reporting Period
Company: 180 Life Sciences Corp. (Note: Metadata listed "FORUM MARKETS Inc" is incorrect; the filing is for 180 Life Sciences Corp.)
Filing Type: Form 8-K (Current Report)
Date of Report: September 29, 2024 (Event Date)
Reporting Period: Events occurring on September 29 and September 30, 2024.
The Company entered into an Asset Purchase Agreement with Elray Resources, Inc. to acquire source code and intellectual property for an online blockchain casino. The transaction closed on September 30, 2024.
Key Financial Metrics and Transaction Terms
This filing details a strategic acquisition rather than standard periodic financial results. No revenue, profit, or cash flow figures for the reporting period are provided in this text.
- Consideration Paid:
- 1,000,000 shares of newly designated Series B Convertible Preferred Stock.
- Warrants to purchase 3,000,000 shares of common stock.
- Series B Preferred Stock Terms:
- Stated Value: $17.30 per share (Total aggregate liquidation preference: $17,300,000).
- Conversion: Convertible into common stock representing 40% of the Company's outstanding shares upon Stockholder Approval (capped at 10,000,000 shares).
- Dividends: None, except participation in cash dividends on a pro-rata basis with common stock.
- Warrant Terms:
- Exercise Price: $1.68 per share.
- Term: 7 years (through September 30, 2031).
- Conditions: Issuance of shares upon exercise requires Stockholder Approval.
- Post-Closing Support: Elray to provide up to 40 hours/week of assistance for 6 months at no cost.
Material Changes and Nasdaq Compliance
Asset Acquisition: The Company acquired blockchain casino assets, marking a potential pivot or expansion into online gaming operations.
Nasdaq Equity Rule Compliance:
- The Company previously failed to meet the $2,500,000 stockholders' equity requirement for Nasdaq listing.
- A delisting determination was stayed pending a hearing, which granted an extension to regain compliance.
- Current Status: The Company believes the issuance of the Series B Preferred Stock and Warrants has restored compliance with the Equity Rule as of the filing date.
- Deadline: The Company must file a public disclosure and income projections by October 15, 2024, to finalize compliance.
Guidance, Risks, and Contingencies
- Stockholder Approval Required: The issuance of Conversion Shares and Warrant Shares is contingent upon stockholder approval via a proxy statement. No shares may be issued until this approval is received.
- Delisting Risk: There is no assurance that Nasdaq will agree the Company has regained compliance. Failure to comply by the October 15, 2024 deadline could result in delisting, impairing liquidity and capital raising ability.
- Operational Risks: The Company requires front-end development to launch the casino operation. While Elray will assist, the Company retains sole discretion on vendors and bears the cost of front-end development.
- Forward-Looking Statements: The filing contains projections regarding compliance and future operations which are subject to risks and uncertainties.
Investor Verification Checklist
- Verify the filing of the Proxy Statement and the date of the upcoming stockholder meeting for approval of the Series B conversion and Warrants.
- Confirm the Company's receipt of a formal compliance determination from Nasdaq by October 15, 2024.
- Review the full Asset Purchase Agreement (Exhibit 2.1) for specific representations regarding the quality and ownership of the blockchain casino IP.
- Monitor the Company's ability to secure payment gateways and necessary gaming licenses, as these are critical to the asset's utility.
- Assess the dilution impact of the Series B Preferred Stock, which is designed to represent 40% of the outstanding common stock upon conversion.